Brought to you by 
Series C leads to $20mm for PrimeraDx
19 Mar 2013
Executive Summary
Molecular diagnostics firm PrimeraDx raised $20mm in its Series C financing led by first-time backer CHL Medical Partners, which adds a board member. Returning shareholders Abingworth, InterWest Partners, Malaysian Technology Development Corp., MPM Capital, Burrill & Co., and Invus Group also participated. The company will use some of the funds to continue developing assays that are run on its ICEPlex system.
Deal Industry
- In Vitro Diagnostics
-
Research, Analytical Equipment & Supplies
- PCR & Amplification Tools
-
In Vitro Diagnostics
- Molecular Diagnostics & Genetic Testing
-
Biotechnology
- Pharmacogenetics-Pharmacogenomics
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Series C leads to $20mm for PrimeraDx
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice